215 related articles for article (PubMed ID: 1355402)
1. Genetic markers as prognostic indicators in breast cancer.
Wolman SR; Pauley RJ; Mohamed AN; Dawson PJ; Visscher DW; Sarkar FH
Cancer; 1992 Sep; 70(6 Suppl):1765-74. PubMed ID: 1355402
[TBL] [Abstract][Full Text] [Related]
2. INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.
Pauley RJ; Gimotty PA; Paine TJ; Dawson PJ; Wolman SR
Breast Cancer Res Treat; 1996; 37(1):65-76. PubMed ID: 8750529
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy.
Watatani M; Nagayama K; Imanishi Y; Kurooka K; Wada T; Inui H; Hirai K; Ozaki M; Yasutomi M
Breast Cancer Res Treat; 1993 Dec; 28(3):231-9. PubMed ID: 7912561
[TBL] [Abstract][Full Text] [Related]
4. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
5. [The significance of c-erbB-2 and int-2 gene alterations and DNA ploidy pattern for aggressiveness of breast cancer].
Nagayama K; Watatani M; Maeda S; Imanishi Y; Kurooka K; Wada T; Yasutomi M
Nihon Geka Gakkai Zasshi; 1993 Oct; 94(10):1144-52. PubMed ID: 7901748
[TBL] [Abstract][Full Text] [Related]
6. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
7. A paradigm for oncogene complementation in human breast cancer.
Roux-Dosseto M; Martin PM
Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors.
Nagai MA; Marques LA; Torloni H; Brentani MM
Oncology; 1993; 50(6):412-7. PubMed ID: 7901824
[TBL] [Abstract][Full Text] [Related]
9. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
10. Amplification of fgfr4 gene in human breast and gynecological cancers.
Jaakkola S; Salmikangas P; Nylund S; Partanen J; Armstrong E; Pyrhönen S; Lehtovirta P; Nevanlinna H
Int J Cancer; 1993 May; 54(3):378-82. PubMed ID: 8099571
[TBL] [Abstract][Full Text] [Related]
11. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
12. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
[TBL] [Abstract][Full Text] [Related]
13. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
[TBL] [Abstract][Full Text] [Related]
14. GST pi gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers.
Saint-Ruf C; Malfoy B; Scholl S; Zafrani B; Dutrillaux B
Oncogene; 1991 Mar; 6(3):403-6. PubMed ID: 1826346
[TBL] [Abstract][Full Text] [Related]
15. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis.
Borg A; Zhang QX; Olsson H; Wenngren E
Genes Chromosomes Cancer; 1992 Nov; 5(4):311-20. PubMed ID: 1283319
[TBL] [Abstract][Full Text] [Related]
17. Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma.
Soini Y; Mannermaa A; Winqvist R; Kamel D; Poikonen K; Kiviniemi H; Pääkkö P
J Histochem Cytochem; 1994 Jun; 42(6):795-803. PubMed ID: 7910618
[TBL] [Abstract][Full Text] [Related]
18. Classical gene amplifications in human breast cancer are not associated with distant solid metastases.
Driouch K; Champème MH; Beuzelin M; Bièche I; Lidereau R
Br J Cancer; 1997; 76(6):784-7. PubMed ID: 9310246
[TBL] [Abstract][Full Text] [Related]
19. Significance of c-erbB-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer.
Babiak J; Hugh J; Poppema S
Cancer; 1992 Aug; 70(4):770-6. PubMed ID: 1353701
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-risk breast cancer patients from genetic changes of their tumors.
Watatani M; Inui H; Nagayama K; Imanishi Y; Nishimura K; Hashimoto Y; Yamauchi E; Hojo T; Kotsuma Y; Yamato M; Matsunami N; Yasutomi M
Surg Today; 2000; 30(6):516-22. PubMed ID: 10883462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
